Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web


  Free Subscription


2 Ann Hematol
1 Biochem Biophys Res Commun
2 Blood
2 Eur J Haematol
1 Int J Hematol
1 J Clin Oncol
1 J Natl Cancer Inst
1 Leuk Res

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Hematol

  1. BILL M, Grimm J, Jentzsch M, Kloss L, et al
    Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Ann Hematol. 2018 May 22. pii: 10.1007/s00277-018-3373.
    PubMed     Text format     Abstract available

  2. ALLAIN EP, Venzl K, Caron P, Turcotte V, et al
    Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients.
    Ann Hematol. 2018 May 21. pii: 10.1007/s00277-018-3356.
    PubMed     Text format     Abstract available

    Biochem Biophys Res Commun

  3. SHEN X, Xing S, Zhang L, Wang F, et al
    Vibsanin A sensitizes human acute myeloid leukemia cells to tyrosine kinase inhibitor-induced myeloid differentiation via activation of PKC and upregulation of Lyn.
    Biochem Biophys Res Commun. 2018 May 19. pii: S0006-291X(18)31198.
    PubMed     Text format     Abstract available


  4. TESTI AM, Pession A, Diverio D, Grimwade D, et al
    Risk-adapted treatment of acute promyelocytic leukemia: results from International Consortium for Childhood APL.
    Blood. 2018 May 22. pii: blood-2018-03-836528. doi: 10.1182/blood-2018-03-836528
    PubMed     Text format     Abstract available

  5. MAIFREDE S, Nieborowska-Skorska M, Sullivan K, Dasgupta Y, et al
    Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
    Blood. 2018 May 21. pii: blood-2018-02-834895. doi: 10.1182/blood-2018-02-834895
    PubMed     Text format     Abstract available

    Eur J Haematol

  6. GLAVEY S, Quinn J, McCloy M, Sargent J, et al
    Emergence of Bruton's Tyrosine Kinase-negative Hodgkin Lymphoma During Ibrutinib Treatment of Chronic Lymphocytic Leukaemia.
    Eur J Haematol. 2017 May 31. doi: 10.1111/ejh.12911.
    PubMed     Text format     Abstract available

  7. BALL S, Vutthikraivit W, Maiti A, Short NJ, et al
    Infection with Ibrutinib in patients with Chronic Lymphocytic Leukemia (CLL): How strong is the association?
    Eur J Haematol. 2018 May 23. doi: 10.1111/ejh.13098.
    PubMed     Text format     Abstract available

    Int J Hematol

  8. TOMOYASU C, Imamura T, Tomii T, Yano M, et al
    Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.
    Int J Hematol. 2018 May 21. pii: 10.1007/s12185-018-2474.
    PubMed     Text format     Abstract available

    J Clin Oncol

  9. LETAI A
    Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2018 May 22:JCO2018782763. doi: 10.1200/JCO.2018.78.2763.
    PubMed     Text format    

    J Natl Cancer Inst

  10. FELLAH S, Cheung YT, Scoggins MA, Zou P, et al
    Brain Activity Associated With Attention Deficits Following Chemotherapy for Childhood Acute Lymphoblastic Leukemia.
    J Natl Cancer Inst. 2018 May 21. pii: 5001111. doi: 10.1093.
    PubMed     Text format     Abstract available

    Leuk Res

  11. SMITH MR, Weiss RF
    Optimal use of novel agents in chronic lymphocytic leukemia.
    Leuk Res. 2018;70:37-40.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.